$2.31 Billion is the total value of Avoro Capital Advisors LLC's 32 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | IMMUNOMEDICS INC | $340,295,000 | +34.6% | 17,714,461 | 0.0% | 14.72% | -2.6% | |
| XENE | XENON PHARMACEUTICALS INC | $24,384,000 | +61.0% | 2,400,000 | 0.0% | 1.05% | +16.5% | |
| INTEC PHARMA LTD | $18,325,000 | -2.8% | 2,500,000 | 0.0% | 0.79% | -29.7% | ||
| PCRX | PACIRA PHARMACEUTICALS INC | $15,224,000 | -11.5% | 400,000 | 0.0% | 0.66% | -36.1% | |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC | $11,419,000 | -12.3% | 475,000 | 0.0% | 0.49% | -36.6% | |
| ALIM | ALIMERA SCIENCES INC | $6,614,000 | +47.6% | 6,240,000 | 0.0% | 0.29% | +6.7% | |
| FENC | FENNEC PHARMACEUTICALS INC | $5,364,000 | -24.0% | 1,105,999 | 0.0% | 0.23% | -45.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.